As of 1:31 p.m. on October 29, GC Pharma is trading at 273,500 KRW, up 1.3% from the previous day. The trading volume stands at 307,525 shares, which is 66.45% of the previous day's volume. GC Pharma is known as a pharmaceutical company specializing in blood products and vaccines.
On October 26, Geunhee Seo, a researcher at Samsung Securities, stated, "A CMO contract has been signed for 500 million doses of Fill & Finish (final product) for CEPI (Coalition for Epidemic Preparedness Innovations) and the COVID-19 vaccine, covering the period from March 2021 to May 2022. The existing Fill & Finish production capacity, including the recently completed Ochang Integrated Fill & Finish Center, is 800 million doses. The estimated production cost per dose is $1. As multiple main contracts have been signed with companies supported by CEPI, the estimated production scale is expected to be revised upward." Based on this, the target price for GC Pharma was set at 320,000 KRW.
Over the past five days, individual investors have recorded a net sale of 251,296 shares of GC Pharma. In contrast, foreign investors and institutions have recorded net purchases of 89,266 shares and 146,571 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro
※ This article was automatically generated in real time by a news algorithm jointly developed by Asia Economy and the financial AI company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![User Who Sold Erroneously Deposited Bitcoins to Repay Debt and Fund Entertainment... What Did the Supreme Court Decide in 2021? [Legal Issue Check]](https://cwcontent.asiae.co.kr/asiaresize/183/2026020910431234020_1770601391.png)
